AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 779473
Drug: Parasympatholytic drug
RxNorm normalized name: Bos taurus parasympathetic nerve preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Parasympatholytic drug therapy (propantheline bromide or dycyclomine HC1)
Trial: 27670440
Drug: CoQ10 100
RxNorm normalized name: Walgreens CoQ10 100mg Softgel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CoQ10 100 mg daily
Trial: 27670440
Drug: Control (current
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (current preventive drugs only)
Trial: 19494028
Drug: CLA-mix (5.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CLA-mix (5.5 g/d of 40/40% of cis9,trans11-CLA and trans10,cis12-CLA)
Trial: 16340945
Drug: Changes in
RxNorm normalized name: guaifenesin / hydrocodone bitartrate Oral Solution [Canges XP]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Changes in biological CVD risk markers
Trial: 17986538
Drug: Usual daily
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Usual daily exit-site care without mupirocin (Group C)
Trial: 1399992
Drug: 4% lidocaine
RxNorm normalized name: Lidocaine 344 mg TOPICAL PATCH [Pain Relief 4% Lidocaine]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4% lidocaine applied to the oral and nasal mucosa
Trial: 6091169
Drug: Azathioprine and
RxNorm normalized name: Azathioprine
DrugBank: Azathioprine (DB00993)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Azathioprine and low-dose prednisolone
Trial: 28166780
Drug: High protein
RxNorm normalized name: Vital High Protein
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High protein diet (1.3 g/kg body weight) without resistance exercise
Trial: 28166780
Drug: Normal protein
RxNorm normalized name: protein C
DrugBank: Protein C (DB11312)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal protein diet (0.8 g/kg) with resistance exercise 3 times/week
Trial: 28166780
Drug: Normal protein
RxNorm normalized name: protein C
DrugBank: Protein C (DB11312)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal protein diet (0.8 g/kg) without resistance exercise
Trial: 18059467
Drug: Amino acid
RxNorm normalized name: Amino Acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amino acid levels on day 7 of age during parenteral nutrition phase
Trial: 16226864
Drug: Slow spinal
RxNorm normalized name: Slow Sodium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Slow spinal injection (60 seconds) of 10 mg of hyperbaric bupivacaine 0.5% with 25 microg of fentanyl and 100 microg of morphine (group L)
Trial: 14505907
Drug: 0.5mg dose
RxNorm normalized name: OZEMPIC 0.25mg or 0.5mg Dose 2mg/3mL Pen Injector
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5mg dose of L2-108/120 peptide
Trial: 14505907
Drug: 0.1mg dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.1mg dose of L2-108/120 peptide
Trial: 11514043
Drug: Streptococcus pneumoniae
RxNorm normalized name: Streptococcus pneumoniae
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Streptococcus pneumoniae conjugate vaccine
Trial: 29788347
Drug: Vaccine intervention
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vaccine intervention
Trial: 3492497
Drug: Urea administered
RxNorm normalized name: Urea
DrugBank: Urea (DB03904)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Urea administered during cardiopulmonary bypass (CPB)
Trial: 18258295
Drug: Resin cement
RxNorm normalized name: Quick Cure resin cement
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Resin cement (Rely‐X Arc, 3M) with metal tribochemically treated (Group G)
Trial: 18258295
Drug: Resin cement
RxNorm normalized name: Quick Cure resin cement
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Resin cement (Compolute, 3M) with no surface treatment (Group B)
Trial: 8173194
Drug: 5-fluorouracil (5-FU)
RxNorm normalized name: 5-FU
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 5-fluorouracil (5-FU) given by continuous infusion (96 h) iv and ip, modulated by high-dose folinic acid-iv
Trial: 22911473
Drug: NPM1+/FLT3-ITD- subgroup
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NPM1+/FLT3-ITD- subgroup (allo-HSCT, auto-HSCT, chemotherapy)
Trial: 18991473
Drug: Cyclobenzaprine extended
RxNorm normalized name: cyclobenzaprine Extended Release Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cyclobenzaprine extended release (CER) 30 mg once daily
Trial: 18991473
Drug: Cyclobenzaprine immediate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cyclobenzaprine immediate release (CIR) 10 mg three times daily
Trial: 16274373
Drug: Acetaminophen (3,000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acetaminophen (3,000 mg/d)
Trial: 11862365
Drug: High-dose ascorbic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose ascorbic acid (3 x 1000 mg/day Cetebe)
Trial: 2692022
Drug: Theophylline 390-900
RxNorm normalized name: Theophylline
DrugBank: Theophylline (DB00277)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Theophylline 390-900 mg daily (1/3 in the morning, 2/3 in the evening)
Trial: 2692022
Drug: Terbutaline 15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Terbutaline 15 mg daily (7.5 mg in the morning and 7.5 mg in the evening)
Trial: 11524396
Drug: Atrial therapies
RxNorm normalized name: Echinacea, aerial parts
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atrial therapies 'on' (pacing and shock therapies)
Trial: 24736085
Drug: Placebo plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo plus 150 mg/day erlotinib (P/E)
Trial: 24736085
Drug: 400 mg/day
RxNorm normalized name: ribociclib succinate 400 mg/day (200 mg x 2) ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400 mg/day apricoxib plus 150 mg/day erlotinib (AP/E) in patients aged 65 years or younger
Trial: 1817934
Drug: AmF/SnF2 mouth
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AmF/SnF2 mouth rinse solution, rinsed 1x/d for 16 months
Trial: 7006182
Drug: Atenolol, 50
RxNorm normalized name: Atenolol, 50 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atenolol, 50 mg, b.i.d.
Trial: 7006182
Drug: Propranolol, 80
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propranolol, 80 mg, b.i.d.
Trial: 31149004
Drug: Ketofol (ketamine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketofol (ketamine 25 µg/kg/min + propofol 75 µg/kg/min)
Trial: 29123173
Drug: Vitamin D
RxNorm normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin D supplementation (100,000 IU bolus followed by 4,000 IU daily cholecalciferol)
Trial: 22284287
Drug: Relaxin (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Relaxin (50 μg weekly injections for 8 weeks)
Trial: 22284287
Drug: Placebo (weekly
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (weekly injections for 8 weeks)
Trial: 17882138
Drug: Hydroxypropylmethylcellulose (HPMC)
DrugBank: Hypromellose (DB11075)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydroxypropylmethylcellulose (HPMC) at 15 g day(‐1) for 1 week (medium, high, ultra-high viscosity)
Trial: 17882138
Drug: Hydroxypropylmethylcellulose (HPMC)
DrugBank: Hypromellose (DB11075)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydroxypropylmethylcellulose (HPMC) at 5 g day(‐1) for 8 weeks
Trial: 17882138
Drug: Hydroxypropylmethylcellulose (HPMC)
DrugBank: Hypromellose (DB11075)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydroxypropylmethylcellulose (HPMC) at 15 g day(‐1) for 8 weeks
Trial: 15144295
Drug: 0.1 mg
RxNorm normalized name: biotin 0.1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.1 mg x kg(‐1) nefopam
Trial: 11932287
Drug: Antiresorptive agents
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antiresorptive agents
Trial: 9691099
Drug: Isotretinoin treatment
RxNorm normalized name: Isotretinoin
DrugBank: Isotretinoin (DB00982)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Isotretinoin treatment (80 mg/d; 5 d)
Trial: 9691099
Drug: LG1069 (RXR-specific
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LG1069 (RXR-specific agonist)
Trial: 8583465
Drug: Intravenous captopril
RxNorm normalized name: Captopril
DrugBank: Captopril (DB01197)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous captopril 1.25 mg
Trial: 2529815
Drug: Teicoplanin (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Teicoplanin (3 to 7 mg/kg every 12 h on the first day, followed by 3 to 7 mg/kg every 24 h; or 8 to 14.4 mg/kg per day for some cases)
Trial: 2529815
Drug: Teicoplanin combined
RxNorm normalized name: teicoplanin
DrugBank: Teicoplanin (DB06149)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Teicoplanin combined with one or more antibiotics
Trial: 360901
Drug: Ribavirin (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ribavirin (300 mg/day, administered as capsules three times daily for 5 days)
Trial: 30681017
Drug: SHP465 mixed
RxNorm normalized name: Humalog Mix
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SHP465 mixed amphetamine salts (25/50 mg)
Trial: 15122768
Drug: Infliximab (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Infliximab (10 mg/kg) with prednisolone (40 mg/day for 28 days)
Trial: 15122768
Drug: Placebo with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo with prednisolone (40 mg/day for 28 days)
Trial: 7625110
Drug: Administration of
RxNorm normalized name: IV solutions used in parenteral administration of fluids, electrolytes and nutrients
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administration of vaccine at STD clinic (centre A)
Trial: 2122710
Drug: Intravenous taurine
RxNorm normalized name: Taurine
DrugBank: Taurine (DB01956)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intravenous taurine (10 mg.kg‐1.d‐1)
Trial: 211011
Drug: Buccal administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Buccal administration of 500 μg of fenoterol
Trial: 211011
Drug: Inhalation of
RxNorm normalized name: Ocean brand of sodium chloride Inhalant Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhalation of 200 μg of fenoterol
Trial: 211011
Drug: Inhalation of
RxNorm normalized name: Ocean brand of sodium chloride Inhalant Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhalation of 400 μg of fenoterol
Trial: 30636725
Drug: Combination EMG‐controlled
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination EMG‐controlled electrical stimulation with visual EMG biofeedback group (CBG)
Trial: 27268381
Drug: Carbetocin (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carbetocin (100 μg IV)
Trial: 26047975
Drug: 1 mg
RxNorm normalized name: biotin 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mg TA-8995
Trial: 26047975
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg TA-8995 plus 20 mg atorvastatin
Trial: 26047975
Drug: 5 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg TA-8995
Trial: 8355929
Drug: 1.5 mg
RxNorm normalized name: boron 1.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.5 mg recombinant human relaxin in 3% methylcellulose gel
Trial: 30971241
Drug: Late PMDI
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Late PMDI (periarticular multimodal drug injection) administered before prosthetic implantation
Trial: 30971241
Drug: Early PMDI
RxNorm normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Early PMDI (periarticular multimodal drug injection) administered just after knee arthrotomy
Trial: 21896129
Drug: Ceramide-containing emulsion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ceramide-containing emulsion cream
Trial: 11269462
Drug: Low-dose aprotinin
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose aprotinin (2 x 10(6) kallikrein inhibitor units)
Trial: 11269462
Drug: Epsilon aminocaproic
RxNorm normalized name: Epsilon Aminocaproic Acid
DrugBank: Aminocaproic acid (DB00513)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Epsilon aminocaproic acid (EACA) (20 g)
Trial: 9505147
Drug: Metformin treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin treatment for 12 weeks
Trial: 9505147
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (diet and lifestyle advice and lovastatin 40 mg/dag during a 4-week run-in period)
Trial: 9505147
Drug: Non-obese patients
RxNorm normalized name: Tavist Non-Sedating
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-obese patients receiving Metformin
Trial: 2643167
Drug: Nisoldipine 10
RxNorm normalized name: nisoldipine 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nisoldipine 10 to 20 mg once daily
Trial: 125147
Drug: 6-Thioguanine (1.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6-Thioguanine (1.0 mg/kg/day orally)
Trial: 125147
Drug: Procarbazine (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Procarbazine (3 mg/kg/day orally)
Trial: 15920566
Drug: 4 ml
RxNorm normalized name: ethanol 1.4 ML/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 ml lignocaine 2% with sodium hyaluronidase 75 IU/ml (Group B)
Trial: 9570604
Drug: Tetracaine 15
RxNorm normalized name: Chlorhexidine gluconate 500 microgram/mL and tetracaine 150 microgram/mL oromucosal spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tetracaine 15 mg
Trial: 8072050
Drug: Both high-dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both high-dose and low-dose methadone
Trial: 2468872
Drug: Nitrendipine (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nitrendipine (20 mg single oral daily dose for a 3‐week treatment period)
Trial: 31519680
Drug: Enhanced community
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enhanced community case management (CCM) plus monthly screening and treatment (MSAT) using rapid diagnostic tests (RDTs)
Trial: 31519680
Drug: Standard of
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard of care plus enhanced CCM, comprising active weekly screening for fever and detection and treatment of infections in fever positive individuals using RDTs
Trial: 20006254
Drug: Group S7.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group S7.5 (1.5 mL of 0.5% hyperbaric bupivacaine)
Trial: 20006254
Drug: Group S5
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group S5 (1.0 mL of 0.5% hyperbaric bupivacaine)
Trial: 20006254
Drug: Group S4
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group S4 (0.8 mL of 0.5% hyperbaric bupivacaine)
Trial: 9751631
Drug: High-dose cytarabine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose cytarabine (3 g/m2)
Trial: 9751631
Drug: Low-dose cytarabine
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose cytarabine (100 mg/m2)
Trial: 9751631
Drug: All doses
RxNorm normalized name: All Clear
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All doses of cytarabine
Trial: 20798194
Drug: Epoetin alfa
RxNorm normalized name: epoetin alfa
DrugBank: Erythropoietin (DB00016)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Epoetin alfa (10,000 IU 3 times weekly)
Trial: 18756431
Drug: 17alpha-hydroxyprogesterone caproate
RxNorm normalized name: 17alpha-Hydroxyprogesterone hexanoate
DrugBank: Hydroxyprogesterone caproate (DB06789)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 17alpha-hydroxyprogesterone caproate (17P), 341 mg intramuscularly, twice a week until 36 weeks
Trial: 10925686
Drug: HCFU 100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HCFU 100 mg
Trial: 8893355
Drug: Constant inflow
RxNorm normalized name: constant albicans extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Constant inflow (CFlow) administration
Trial: 8893355
Drug: Constant fraction
RxNorm normalized name: constant albicans extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Constant fraction (CF) administration
Trial: 2431395
Drug: Thymostimulin (TP‐1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thymostimulin (TP‐1 Serono: 1.5 mg/kg/die for five days)
Trial: 22539584
Drug: Oral glucose
RxNorm normalized name: glucose Oral Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral glucose challenge (75-g glucose tolerance test)
Trial: 17907110
Drug: Tesaglitazar (0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tesaglitazar (0.5 or 1 mg/day)
Trial: 10616948
Drug: Right Unilateral
RxNorm normalized name: kaolin light
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Right Unilateral ECT (RUL) with fixed high dose (378 mC)
Trial: 10616948
Drug: Bifrontal ECT
RxNorm normalized name: Bos taurus frontal lobe preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bifrontal ECT (BF) with age-based dosing
Trial: 10616948
Drug: Dose-titration method
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dose-titration method
Trial: 9967
Drug: Medazepam (15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medazepam (15 mg)
Trial: 28719592
Drug: TL quadruple
RxNorm normalized name: TL-895
DrugBank: TL-895 (DB16471)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TL quadruple therapy (esomeprazole 40 mg b.d., bismuth 120 mg q.d.s., tetracycline 500 mg q.d.s., and levofloxacin 500 mg o.d.)
Trial: 28719592
Drug: AL triple
RxNorm normalized name: BACITRACIN ZINC 400 [USP'U] in 1 g / NEOMYCIN SULFATE 0.0035 g in 1 g / POLYMYXIN B SULFATE 5000 [USP'U] in 1 g TOPICAL OINTMENT [PROHEAL TRIPLE ANTIBIOTIC]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AL triple therapy (esomeprazole 40 mg b.d., amoxicillin 500 mg q.d.s., and levofloxacin 500 mg o.d.)
Trial: 28719592
Drug: TL quadruple
RxNorm normalized name: TL-895
DrugBank: TL-895 (DB16471)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TL quadruple therapy
Trial: 28719592
Drug: AL triple
RxNorm normalized name: BACITRACIN ZINC 400 [USP'U] in 1 g / NEOMYCIN SULFATE 0.0035 g in 1 g / POLYMYXIN B SULFATE 5000 [USP'U] in 1 g TOPICAL OINTMENT [PROHEAL TRIPLE ANTIBIOTIC]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AL triple therapy
Trial: 25315022
Drug: LED therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LED therapy (625 nm, 4 J/cm²) with Unna's boot
Trial: 25315022
Drug: Placebo treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo treatment with Unna's boot (Control)
Trial: 16816054
Drug: 0.625 mg/d
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.625 mg/d of conjugated estrogens (n = 20)
Trial: 16816054
Drug: Gabapentin titrated
RxNorm normalized name: Gabapentin
DrugBank: Gabapentin (DB00996)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Gabapentin titrated to 2,400 mg/d (n = 20)
Trial: 10702891
Drug: Cilostazol with
RxNorm normalized name: Cilostazol
DrugBank: Cilostazol (DB01166)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cilostazol with aspirin
Trial: 8753934
Drug: Caffeine (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Caffeine (3 mg/kg body weight)
Trial: 6211147
Drug: Heat‐killed sonicated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heat‐killed sonicated suspension of malassezia ovalis
Trial: 6211147
Drug: Heat‐killed sonicated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heat‐killed sonicated suspension of Staphylococcus epidermidis
Trial: 29850709
Drug: Placebo control
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo control (325 mL twice per day for 12 weeks)
Trial: 22828021
Drug: Preventive antiemetic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Preventive antiemetic medication
Trial: 15983321
Drug: Irbesartan (150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Irbesartan (150 mg/day)
Trial: 29420324
Drug: Preoperative mitomycin
RxNorm normalized name: Mitomycin
DrugBank: Mitomycin (DB00305)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Preoperative mitomycin C (MMC) injection (0.1 mL of 0.15 mg/mL MMC) followed by pterygium excision and conjunctival autograft (CAG)
Trial: 24731467
Drug: Soy protein
RxNorm normalized name: Soy Protein
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Soy protein containing 70 mg isoflavone daily for one year
Trial: 21962771
Drug: Oral intervention
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral intervention (O)
Trial: 14719287
Drug: Bufei Keli
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bufei Keli (Chinese drug granules for invigorating the lung)
Trial: 8658373
Drug: Thiorphan 1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thiorphan 1 mg (in 2 ml) followed by ANP 5 mg
Trial: 8658373
Drug: Placebo (saline)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (saline) followed by ANP 5 mg
Trial: 6459776
Drug: Salbutamol 5
RxNorm normalized name: Salbutamol
DrugBank: Albuterol (DB01001)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Salbutamol 5 mg
Trial: 22964703
Drug: Dexpantenolo (pantothenic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexpantenolo (pantothenic acid derivative), administered intravenously during the second and third post-operative day.
Trial: 22964703
Drug: Spinal anesthetic
RxNorm normalized name: Gelato Anesthetic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Spinal anesthetic treatment group.
Trial: 22964703
Drug: Peridural anesthetic
RxNorm normalized name: Gelato Anesthetic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Peridural anesthetic treatment group.
Trial: 15827560
Drug: CLA (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CLA (2 g CLA)
Trial: 15827560
Drug: Linoleic acid
RxNorm normalized name: Linoleic acid
DrugBank: Linoleic acid (DB14104)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Linoleic acid (2 g linoleic acid)
Trial: 12107508
Drug: Intravenous timolol
RxNorm normalized name: timolol
DrugBank: Timolol (DB00373)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intravenous timolol (0.2 mg)
Trial: 12107508
Drug: Ocular timolol
RxNorm normalized name: timolol
DrugBank: Timolol (DB00373)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Ocular timolol (0.2 mg)